Target-specific oral anticoagulants
Although for decades warfarin has been the gold standard for prevention of thromboembolic events, management is complicated by the drug's relatively narrow therapeutic window and the high incidence of interactions. Target-specific oral anticoagulants (TSOAs) are an attractive alternative to warfarin because they do not require routine monitoring and are associated with a low number of clinically relevant drug interactions. TSOAs include dabigatran, apixaban, and rivaroxaban. Pharmacology, dosing, clinical efficacy, and special considerations for these TSOAs are reviewed.
Ricchetti, Charlotte and Shea, Leticia, "Target-specific oral anticoagulants" (2014). Regis University Faculty Publications. 660.